Higher PIK3C2B gene expression of H1N1+ specific B-cells is associated with lower H1N1 immunogenicity after trivalent influenza vaccination in HIV infected children

Higher PIK3C2B gene expression of H1N1+ specific B-cells is associated with lower H1N1 immunogenicity after trivalent influenza vaccination in HIV infected children

Copyright © 2020 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 215(2020) vom: 16. Juni, Seite 108440
1. Verfasser: Cotugno, Nicola (VerfasserIn)
Weitere Verfasser: Zicari, Sonia, Morrocchi, Elena, de Armas, Lesley R, Pallikkuth, Suresh, Rinaldi, Stefano, Ruggiero, Alessandra, Manno, Emma Concetta, Zangari, Paola, Chiriaco, Maria, Bernardi, Stefania, Andrews, Sarah F, Cagigi, Alberto, Rossi, Paolo, McDermott, Adrian B, Pahwa, Savita, Palma, Paolo
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2020
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Antigen specific B cells Gene expression H1N1 Influenza vaccination PIK3C2B Perinatally HIV infected children Antibodies, Viral mehr... Influenza Vaccines Class II Phosphatidylinositol 3-Kinases EC 2.7.1.137 PIK3C2B protein, human
LEADER 01000naa a22002652 4500
001 NLM30914874X
003 DE-627
005 20231225133255.0
007 cr uuu---uuuuu
008 231225s2020 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2020.108440  |2 doi 
028 5 2 |a pubmed24n1030.xml 
035 |a (DE-627)NLM30914874X 
035 |a (NLM)32330555 
035 |a (PII)S1521-6616(19)30410-3 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Cotugno, Nicola  |e verfasserin  |4 aut 
245 1 0 |a Higher PIK3C2B gene expression of H1N1+ specific B-cells is associated with lower H1N1 immunogenicity after trivalent influenza vaccination in HIV infected children 
264 1 |c 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 29.01.2021 
500 |a Date Revised 30.12.2021 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2020 Elsevier Inc. All rights reserved. 
520 |a Perinatally HIV-infected children (PHIV), despite successful antiretroviral therapy, present suboptimal responses to vaccinations compared to healthy-controls (HC). Here we investigated phenotypic and transcriptional signatures of H1N1-specific B-cells (H1N1-Sp) in PHIV, differentially responding to trivalent-influenza-vaccine (TIV), and HC. Patients were categorized in responders (R) and non-responders (NR) according to hemagglutination-inhibition-assay at baseline and 21 days after TIV. No differences in H1N1-Sp frequencies were found between groups. H1N1-Sp transcriptional analysis revealed a distinct signature between PHIV and HC. NR presented higher PIK3C2B and NOD2 expression compared to R, confirmed by downregulation of PIK3C2B in resting-memory of R after H1N1 in-vitro stimulation. In conclusion this study confirms that qualitative rather than quantitative analyses are needed to characterize immune responses in PHIV. These results further suggest that higher PIK3C2B in H1N1-Sp of NR is associated with lower H1N1 immunogenicity and may be targeted by future modulating strategies to improve TIV responses in PHIV 
650 4 |a Journal Article 
650 4 |a Research Support, N.I.H., Extramural 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Antigen specific B cells 
650 4 |a Gene expression 
650 4 |a H1N1 
650 4 |a Influenza vaccination 
650 4 |a PIK3C2B 
650 4 |a Perinatally HIV infected children 
650 7 |a Antibodies, Viral  |2 NLM 
650 7 |a Influenza Vaccines  |2 NLM 
650 7 |a Class II Phosphatidylinositol 3-Kinases  |2 NLM 
650 7 |a EC 2.7.1.137  |2 NLM 
650 7 |a PIK3C2B protein, human  |2 NLM 
650 7 |a EC 2.7.1.137  |2 NLM 
700 1 |a Zicari, Sonia  |e verfasserin  |4 aut 
700 1 |a Morrocchi, Elena  |e verfasserin  |4 aut 
700 1 |a de Armas, Lesley R  |e verfasserin  |4 aut 
700 1 |a Pallikkuth, Suresh  |e verfasserin  |4 aut 
700 1 |a Rinaldi, Stefano  |e verfasserin  |4 aut 
700 1 |a Ruggiero, Alessandra  |e verfasserin  |4 aut 
700 1 |a Manno, Emma Concetta  |e verfasserin  |4 aut 
700 1 |a Zangari, Paola  |e verfasserin  |4 aut 
700 1 |a Chiriaco, Maria  |e verfasserin  |4 aut 
700 1 |a Bernardi, Stefania  |e verfasserin  |4 aut 
700 1 |a Andrews, Sarah F  |e verfasserin  |4 aut 
700 1 |a Cagigi, Alberto  |e verfasserin  |4 aut 
700 1 |a Rossi, Paolo  |e verfasserin  |4 aut 
700 1 |a McDermott, Adrian B  |e verfasserin  |4 aut 
700 1 |a Pahwa, Savita  |e verfasserin  |4 aut 
700 1 |a Palma, Paolo  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 215(2020) vom: 16. Juni, Seite 108440  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:215  |g year:2020  |g day:16  |g month:06  |g pages:108440 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2020.108440  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 215  |j 2020  |b 16  |c 06  |h 108440